Slingshot members are tracking this event:
Agios Pharma (AGIO) to complete Phase 1 Study of AG-881 in patients with Hematologic Malignancies With an IDH1 or IDH2 Mutation in Q1 2018
Do you think this event is important to the companies below? How will it affect their stock price?
-- Seventy-three percent of patients (n=38) had previously received temozolomide and 58% percent (n=30) had previously received radiotherapy.
Slingshot Insights Explained
Jun 01, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 1 Study, Ag-881, Hematologic Malignancies, Idh1 Mutation, Idh2 Mutation, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Open-label